Case Study

Routine Pulmonary CTA with Iodine Mapping

“Subtraction imaging adds diagnostic power to the routine evaluation of patients undergoing pulmonary CTA examinations.”

Mathias Prokop, M.D., Ph.D.
Professor and Chairman of Radiology and Nuclear Medicine
Radboud University Medical Center
Nijmegen, the Netherlands

Patient History
A 67-year-old man presented to the emergency department with dyspnea. A CTA examination of the pulmonary arteries was requested to rule out pulmonary embolism as the cause of his symptoms.

Results

Decreased contrast enhancement in the right apical lung segment as shown on the color iodine maps indicates decreased perfusion. This is consistent with the patient’s clinical presentation of pulmonary embolic disease.
**Technology**

Utilizing a pre- and post-contrast scan, the SURE Subtraction Lung application isolates the iodine signal and displays the result as a color overlay. A dedicated scan mode synchronizes the pre- and post-contrast scans and automatically outputs iodine maps directly to the reading station with no need for additional user interaction.

The key to obtaining accurate results lies with an anatomically aware 3D deformable registration algorithm that compensates for patient motion which may occur between the two scans. This ensures highly accurate iodine signal extraction, with the result superimposed on the post-contrast CTA image as a color overlay to clearly demonstrate even subtle differences in HU attenuation.

**Conclusion**

The addition of iodine maps to pulmonary CTA enables the assessment of the distribution of contrast media in the pulmonary parenchyma. SURE Subtraction Lung can automatically provide iodine maps in every routine pulmonary CTA examination.

---

**Acquisition**

Scanner Model: Aquilion ONE / GENESIS Edition

- **Scan Mode:** Ultra Helical
- **Collimation:** 0.5 mm x 80
- **Exposure:** 100 kV
- **Rotation Time:** 0.275 second
- **Dose Reduction:** AIDR \(^*1\) 3D Enhanced
- **CTDI:** 1.6 mGy pre-contrast/
  3.2 mGy post-contrast
- **DLP:** Total 183.9 mGy∙cm
- **Effective Dose:** 2.57 mSv
- **k-factor:** 0.014 \(^*2\)

\(^*1\) Adaptive Iterative Dose Reduction  

---

**CANON MEDICAL SYSTEMS CORPORATION**

https://global.medical.canon

©Canon Medical Systems Corporation 2017-2018. All rights reserved.

Design and specifications are subject to change without notice.

Model number: TSV-305A MCACT0306EA8 2018-03 CMSC/Produced in Japan


Aquilion ONE, Aquilion ONE GENESIS, \(^*3\)SURESubtraction, \(^*4\)SUREExposure and Made for Life are trademarks of Canon Medical Systems Corporation.

Clinical results may vary due to clinical setting, patient presentation and other factors.